We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+12.15%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.85B
AUM Growth
+$519M
Cap. Flow
+$404M
Cap. Flow %
21.87%
Top 10 Hldgs %
27.4%
Holding
120
New
9
Increased
56
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$54.3M
2
CYBR
CyberArk
CYBR
+$36.5M
3
ABBV icon
AbbVie
ABBV
+$26.6M
4
QLIK
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
+$18.5M
5
IMPV
Imperva, Inc.
IMPV
+$18.2M

Top Sells

Rank Stock Value
1
SNDK
SANDISK CORP
SNDK
+$20.5M
2
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$11.8M
3
CXP
COLUMBIA PROPERTY TRUST, INC.
CXP
+$10.6M
4
VMW
VMware, Inc
VMW
+$8.02M
5
OII icon
Oceaneering
OII
+$7M

Sector Composition

Rank Sector Weight
1 Healthcare 28.49%
2 Technology 26.09%
3 Consumer Discretionary 12.82%
4 Industrials 9.62%
5 Energy 3.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLTC
51
DELISTED
Linear Technology Corp
LLTC
$12.9M 0.7%
292,600
– –
EOG icon
52
EOG Resources
EOG
$77.5B
$12.7M 0.69%
144,800
– –
LGND icon
53
Ligand Pharmaceuticals
LGND
$5.94B
$11.5M 0.62%
181,941
– –
ACAD icon
54
Acadia Pharmaceuticals
ACAD
$4.55B
$11.4M 0.61%
271,100
– –
ININ
55
DELISTED
Interactive Intelligence Group, inc.
ININ
$9.88M 0.53%
222,200
– –
CGNX icon
56
Cognex
CGNX
$10.4B
$9.86M 0.53%
410,000
+50,000
+14% +$1.23M
AYR
57
DELISTED
Aircastle Ltd
AYR
$9.72M 0.53%
428,600
+29,000
+7% +$691K
UFS
58
DELISTED
DOMTAR CORPORATION (New)
UFS
$9.05M 0.49%
218,600
– –
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.56B
$8.61M 0.47%
84,100
+15,100
+22% +$1.17M
STML
60
DELISTED
Stemline Therapeutics, Inc.
STML
$8.29M 0.45%
704,250
+84,050
+14% +$1.17M
SRPT icon
61
Sarepta Therapeutics
SRPT
$1.64B
$7.88M 0.43%
259,100
– –
CLDX icon
62
Celldex Therapeutics
CLDX
$3.02B
$7.28M 0.39%
19,247
– –
NBIX icon
63
Neurocrine Biosciences
NBIX
$18.7B
$7.23M 0.39%
151,400
+13,600
+10% +$577K
XNCR icon
64
Xencor
XNCR
$1.59B
$7.2M 0.39%
327,700
+69,600
+27% +$1.19M
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$11.7B
$7.08M 0.38%
51,800
+11,700
+29% +$1.45M
TSRO
66
DELISTED
TESARO, Inc.
TSRO
$6.78M 0.37%
115,400
+27,700
+32% +$1.59M
PWR icon
67
Quanta Services
PWR
$98.7B
$6.71M 0.36%
232,800
– –
CMRE icon
68
Costamare
CMRE
$1.87B
$6.62M 0.36%
360,200
– –
ZSAN
69
DELISTED
Zosano Pharma Corporation
ZSAN
$6.37M 0.34%
1,255
+71
+6% +$439K
SGEN
70
DELISTED
Seagen Inc. Common Stock
SGEN
$6.2M 0.34%
+128,100
New +$5.29M
TVTX icon
71
Travere Therapeutics
TVTX
$5.33B
$5.47M 0.3%
+165,100
New +$4.52M
ALNY icon
72
Alnylam Pharmaceuticals
ALNY
$27.5B
$5.45M 0.3%
45,500
+3,600
+9% +$430K
SGMO
73
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.35M 0.29%
482,500
– –
CEMP
74
DELISTED
Cempra, Inc.
CEMP
$5.29M 0.29%
153,800
– –
SUPN icon
75
Supernus Pharmaceuticals
SUPN
$2.65B
$4.87M 0.26%
286,600
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Eventide Asset Management held 120 positions worth $1.85B, up 39% from $1.33B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management deployed $404M of net new capital in Q2 2015, opening 9 new positions and adding to 56 existing holdings. Its largest new stake was CyberArk: 570,000 shares worth $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was inContact, Inc., an estimated $443K trimmed.

  • Eventide Asset Management's largest Q2 2015 buy was CyberArk: 570,000 shares worth $35.8M.
  • Eventide Asset Management added most to Celgene Corp in Q2 2015, an estimated $54.3M increase.
  • Eventide Asset Management's biggest Q2 2015 reduction was inContact, Inc., cutting an estimated $443K.
  • Eventide Asset Management fully exited SANDISK CORP in Q2 2015, selling an estimated $20.5M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $1.85B portfolio in Q2 2015.
  • Eventide Asset Management opened 9 new positions and closed 10 in Q2 2015.
  • Eventide Asset Management's portfolio value rose 39% quarter-over-quarter to $1.85B.

Based on Eventide Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.